Evidence map›Paper›PMID 40404554›Full record

ReviewDiagnostic and interventional imaging2025

Molecular imaging of neuroendocrine tumors: Current applications and future trends.

Ivan E Wang, Helen A SaTsu, Allen F Brooks, Rudolf A Werner, Steven P Rowe, Peter J H Scott, Benjamin L Viglianti

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostic and interventional imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis).Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ivan E WangDepartment of Radiology, University of Michigan, Ann Arbor MI 48109 USA.
Helen A SaTsuDepartment of Radiology, University of Michigan, Ann Arbor MI 48109 USA.
Allen F BrooksDepartment of Radiology, University of Michigan, Ann Arbor MI 48109 USA.
Rudolf A WernerDepartment of Nuclear Medicine, LMU University Hospital 80336 Munich, Germany.
Steven P RoweDepartment of Radiology, University of North Carolina, Chapel Hill, NC 27599 USA.
Peter J H ScottDepartment of Radiology, University of Michigan, Ann Arbor MI 48109 USA.
Benjamin L VigliantiDepartment of Radiology, University of Michigan, Ann Arbor MI 48109 USA. Electronic address: bviglia@med.umich.edu.

Funding

Interdepartmental Training in Pharmacological SciencesT32GM140223 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Lori L. Isom · 2021 to 2026
$3.8M
Synthesis of Novel PET Radiotracers for Imaging in Alzheimer’s Disease and Related DisordersR01EB021155 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SANFORD, MELANIE S., SCOTT, PETER JAMES HENRY · 2016 to 2024
$3.2M
NIBIB NIH HHS R01 EB021155NIGMS NIH HHS T32 GM140223
6 · The paper itself

Abstract

The prevalence of neuroendocrine neoplasms (NEN), which include neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), has increasing during recent years. The approval of diagnostic single-photon emission computed tomography and positron emission tomography imaging agents for NEN is an important factor in pushing the development of additional agents using new targets to develop patient-specific, targeted, radiopharmaceuticals. Numerous NEN-specific targets exist, including somatostatin receptors, norepinephrine transport substrates, amino acid transport substrates, and glucagon-like peptide-1 receptor analogues, as well as non-specific targets, such as glucose metabolism. Additionally, there are targets that can be used in combination with current agents to further personalize NEN imaging. In well-differentiated gastroenteropancreatic NET, [

Indexed as

Molecular ImagingNeuroendocrine TumorsForecastingHumansRadiopharmaceuticalsRadiopharmaceuticalsFibroblast activation protein inhibitor (FAPI)Neuroendocrine tumorsNuclear medicinePheochromocytoma, Somatostatin

Identifiers

PMID40404554
PMCPMC12354131

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.